【Portfolio】Co-founder and CMO of Basking Bioscience invited as speaker on 2022 World Stroke Congress Singapore
The 2022 World Stroke Congress opened in Singapore on 26th Oct.?It was hosted by World Stroke Organization, the only global body solely focused on stroke with over 4200 delegates from 104 countries. It assembled the international stroke community to work together to reduce the burden of stroke by delivering improvements in prevention, treatment and support. It offered the latest on clinical trials, state-of-the-art presentations by renowned clinicians and researchers, and updates on the latest guidelines.
On Oct 26, Dr. Shahid Nimjee, the Co-founder and CMO of Basking Bioscience, was invited to make speech on Advances in Neurosurgical ICH Approaches in the Onsite Stroke and Live Streamed Session
Hightlights of Dr. Shahid Nimjee
Co-founder and CMO, Basking Bioscience
Assoc. Professor, Neurosurgery Ohio State University
About Basking?
Basking is developing the first in class agent (BB-031) targeting von Willebrand Factor (VWF) along with a direct acting reversal agent (BB-025) to immediately the pharmacological effect of BB-031 in the event of bleeding. BB-031 is an RNA aptamer optimized for rapid onset of action and short duration of effect. Basking will initiate a Phase 2 trial in acute ischemic stroke in late 2022 and is exploring further application in pulmonary embolism in preclinical studies. The technology is based on two decades of translational research on RNA aptamers as therapeutic agents for cardiovascular diseases.
About World Stroke Congress
worldstrokecongress.org